PCSK9 Rekombinanter Antikörper

PCSK9 Rekombinant Antikörper für WB, IF/ICC, FC (Intra), ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human

Anwendung

WB, IF/ICC, FC (Intra), ELISA

Konjugation

Unkonjugiert

CloneNo.

241395G1

Kat-Nr. : 84172-4-RR

Synonyme

241395G1, EC:3.4.21.-, FH3, HCHOLA3, LDLCQ1



Geprüfte Anwendungen

Erfolgreiche Detektion in WBHepG2-Zellen
Erfolgreiche Detektion in IF/ICCHepG2-Zellen
Erfolgreiche Detektion in FC (Intra)HeLa-Zellen

Empfohlene Verdünnung

AnwendungVerdünnung
Western Blot (WB)WB : 1:500-1:2000
Immunfluoreszenz (IF)/ICCIF/ICC : 1:200-1:800
Durchflusszytometrie (FC) (INTRA)FC (INTRA) : 0.25 ug per 10^6 cells in a 100 µl suspension
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, check data in validation data gallery

Produktinformation

84172-4-RR bindet in WB, IF/ICC, FC (Intra), ELISA PCSK9 und zeigt Reaktivität mit human

Getestete Reaktivität human
Wirt / Isotyp Kaninchen / IgG
Klonalität Rekombinant
Typ Antikörper
Immunogen Rekombinantes Protein
Vollständiger Name proprotein convertase subtilisin/kexin type 9
Berechnetes Molekulargewicht74 kDa
Beobachtetes Molekulargewicht 72-78 kDa, 62 kDa
GenBank-ZugangsnummerNM_174936.4
Gene symbol PCSK9
Gene ID (NCBI) 255738
Konjugation Unkonjugiert
Form Liquid
Reinigungsmethode Protein-A-Reinigung
Lagerungspuffer PBS with 0.02% sodium azide and 50% glycerol
LagerungsbedingungenBei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a crucial protein governing the circulating levels of low density lipoprotein-cholesterol (LDL-C), by virtue of its pivotal role in the degradation of the LDL receptor (LDLR). PCSK9 is expressed in the kidney and lung. It is synthesized as a 72 kDa immature precursor that undergoes autocatalytic cleavage in the endoplasmic reticulum to generate a 63 kDa mature protein. The cleaved N-terminal fragment remains associated with the mature protein and is necessary for its secretion, allowing it to circulate in the blood. The ability of PCSK9 to regulate a diverse group of cell-surface proteins hinted that it might also be able to influence additional membrane proteins that are important in anti-tumour immune responses. Targeting PCSK9 to treat cancer is also attractive because two neutralizing antibodies against it, evolocumab and alirocumab, have already been approved for human clinical use to lower cholesterol levels. (PMID: 30522786, PMID: 22493497)

Protokolle

PRODUKTSPEZIFISCHE PROTOKOLLE
WB protocol for PCSK9 antibody 84172-4-RRProtokoll herunterladen
IF protocol for PCSK9 antibody 84172-4-RRProtokoll herunterladen
STANDARD-PROTOKOLLE
Klicken Sie hier, um unsere Standardprotokolle anzuzeigen